-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-518251-31-00
5
patients hospitalized for a septic shock with hypercontractlity
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2024-519818-31-01
5
Endometrial Cancer
Advanced, Recurrent, Metastatic, or Primary Unresec
-
2025-521199-80-00
4
Patients with previously untreated symptomatic chronic lymphocytic leu
-
2025-524408-30-01
5
Metastatic hormone-sensitive prostate cancer
-
2025-524759-29-00
9
Vulvar Squamous Cell Carcinoma (VSCC) patients
-
2024-518359-47-00
10
2025-06-17
Acute Myeloid Leukemia
-
2023-505486-92-00
4
2024-02-09
Small bowel adenocarcinoma
-
2023-505766-28-00
10
2022-10-10
Hereditary angioedema
-
2023-505046-26-00
5
2026-05-07
Colon carcinoma
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-518358-17-00
4
2025-10-06
Squamous cell carcinoma of the esophagus
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-515875-36-00
4
2025-08-18
Advanced biliary tract cancer (BTC)
-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2023-504831-42-00
5
2025-06-27
patient with colorectal cancer with hepatic metastasis
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-508798-94-00
5
2025-02-11
Heart failure
-
2024-510772-20-00
4
2025-02-06
Rectal cancer locally advanced with microsatellite unstable or mismatc
-
2023-509963-25-00
4
2025-01-17
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer
-
2024-516109-21-00
5
2024-12-09
Polycythaemia Vera (PV)